Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
| Revenues: |
| IDD | 103.6 | 93.2 | 78.2 | 81.8 | | | | |
| Sample Processing | 14.5 | 14.4 | 14.3 | 13.7 | 12.3 | 11.2 | 9.6 | 8.3 |
| Personalized Medicine | 0.2 | 0.1 | | | | | | |
| IVD | | | | | 72.0 | 60.8 | 55.0 | 35.3 |
| Total revenues | 118.3 | 107.7 | 92.6 | 95.5 | 84.3 | 72.1 | 64.6 | 43.7 |
| Revenue growth [+] | 9.9% | 16.3% | -3.1% | 13.3% | 17.0% | 11.6% | 48.0% | 39.3% |
| IDD | 11.2% | 19.1% | -4.3% | | | | | |
| Sample Processing | 0.9% | 0.5% | 4.4% | 11.8% | 9.3% | 16.9% | 15.2% | 37.3% |
| Personalized Medicine | 178.3% | | | | | | | |
| IVD | | | | | 18.4% | 10.7% | 55.7% | 39.7% |
| Cost of goods sold | 58.1 | 52.8 | 43.9 | 46.5 | 42.0 | 37.3 | 33.4 | 22.3 |
| Gross profit | 60.2 | 54.9 | 48.7 | 49.0 | 42.3 | 34.8 | 31.2 | 21.4 |
| Gross margin | 50.9% | 51.0% | 52.6% | 51.3% | 50.2% | 48.3% | 48.4% | 49.0% |
| Selling, general and administrative [+] | 42.2 | 37.2 | 29.4 | 27.7 | 23.1 | 20.7 | 17.3 | 13.0 |
| Sales and marketing | 23.1 | 19.8 | 16.1 | 15.7 | 13.1 | 10.7 | 10.1 | 7.2 |
| General and administrative | 19.1 | 17.4 | 13.3 | 12.0 | 10.0 | 10.0 | 7.1 | 5.8 |
| Research and development | 16.2 | 14.6 | 11.4 | 10.4 | 10.3 | 13.1 | 5.0 | 3.9 |
| Other operating expenses | -1.2 | | | | | | | |
| EBITDA [+] | 8.3 | 7.3 | 11.3 | 14.1 | 11.6 | 3.2 | 10.8 | 6.2 |
| EBITDA growth | 14.2% | -35.8% | -19.6% | 21.8% | 262.7% | -70.3% | 73.6% | 1226.8% |
| EBITDA margin | 7.0% | 6.8% | 12.2% | 14.8% | 13.7% | 4.4% | 16.7% | 14.2% |
| Depreciation and amortization | 5.3 | 4.2 | 3.5 | 3.1 | 2.6 | 2.1 | 1.8 | 1.7 |
| EBIT [+] | 3.0 | 3.1 | 7.8 | 11.0 | 9.0 | 1.0 | 8.9 | 4.5 |
| EBIT growth | -4.0% | -60.2% | -28.8% | 22.5% | 753.5% | -88.3% | 100.2% | -922.3% |
| EBIT margin | 2.5% | 2.9% | 8.4% | 11.5% | 10.6% | 1.5% | 13.8% | 10.2% |
| Non-recurring items [+] | 7.4 | | | | | | | |
| Asset impairment | 5.8 | | | | | | | |
| Interest income, net [+] | 1.1 | 1.1 | 0.8 | 1.2 | 1.5 | 1.1 | 0.6 | -0.1 |
| Interest expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 |
| Interest income | 1.1 | 1.1 | 0.9 | 1.2 | 1.5 | 1.1 | 0.6 | 0.1 |
| Other income (expense), net [+] | 0.2 | -0.1 | 0.1 | 1.2 | 0.0 | 0.0 | 0.0 | -0.5 |
| Gain (loss) on foreign currency transactions | 0.2 | -0.1 | 0.1 | | | | | |
| Pre-tax income | -3.1 | 4.1 | 8.7 | 13.4 | 10.4 | 2.1 | 9.5 | 3.8 |
| Income taxes | -1.9 | 1.1 | 2.5 | 4.4 | 2.8 | 2.3 | 3.4 | 1.5 |
| Tax rate | 61.1% | 26.3% | 28.2% | 32.6% | 27.4% | 108.2% | 35.8% | 40.0% |
| Net income | -1.2 | 3.0 | 6.3 | 9.0 | 7.5 | -0.2 | 6.1 | 2.3 |
| Net margin | -1.0% | 2.8% | 6.8% | 9.4% | 9.0% | -0.2% | 9.5% | 5.2% |
| |
| Basic EPS [+] | ($0.07) | $0.17 | $0.35 | $0.49 | $0.42 | ($0.01) | $0.37 | $0.16 |
| Growth | -139.4% | -51.8% | -28.6% | 19.0% | -4335.0% | -102.7% | 132.0% | -434.6% |
| Diluted EPS [+] | ($0.07) | $0.17 | $0.35 | $0.48 | $0.40 | ($0.01) | $0.35 | $0.14 |
| Growth | -139.7% | -51.7% | -27.3% | 19.5% | -4208.0% | -102.8% | 140.9% | -405.8% |
| |
| Shares outstanding (basic) [+] | 17.8 | 17.9 | 17.7 | 18.2 | 18.2 | 17.9 | 16.8 | 14.5 |
| Growth | -0.5% | 1.0% | -2.8% | 0.3% | 1.9% | 6.5% | 15.9% | 28.6% |
| Shares outstanding (diluted) [+] | 17.8 | 18.0 | 17.9 | 18.7 | 18.7 | 17.9 | 17.7 | 15.8 |
| Growth | -1.1% | 0.8% | -4.6% | -0.1% | 5.0% | 1.1% | 11.6% | 40.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|